Stock Price & Analysis

The S1 support level for LYEL Stock is $0.56 ,The R1 resistant level for LYEL Stock is $0.74.

As of the end of day on 2025-02-28, the price of LYEL Stock was $0.709.

The target price for LYEL Stock according to analyst rating is 2.30, with the highest price target at 4.00 and the lowest at 0.60. Analysts have a Moderate Sell rating on LYEL Stock overall.

The market cap of LYEL is $208.3M.

Lyell Immunopharma, Inc. is a T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company’s technologies are designed to generate T cells with the ability to persist and self renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Its technologies can be applied in a target agnostic manner to multiple T cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies. Its product candidates include LYL797, LYL845 and LYL119. The LYL119 is a ROR1 CAR T-cell product designed for enhanced cytotoxicity.

LYEL has a total of 224 employees.